Publication: Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease.
Loading...
Identifiers
Date
2016-01-19
Authors
Taxonera, Carlos
Barreiro-de-Acosta, Manuel
Bastida, Guillermo
Martinez-Gonzalez, Javier
Merino, Olga
Garcia-Sanchez, Valle
Gisbert, Javier P
Marín-Jimenez, Ignacio
Lopez-Serrano, Pilar
Gomez-Garcia, Maria
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press
Abstract
The aims of this study were to evaluate the frequency of entero-urinary fistulas in a cohort of Crohn's disease (CD) patients and to analyse the outcomes of medical and surgical therapy. This multicentre retrospective study included all CD patients with entero-urinary fistulas diagnosed by the presence of clinical symptoms and confirmed at surgery or by radiological or endoscopic techniques. We evaluated outcomes of medical and surgical therapy. We defined remission as absence of clinical symptoms with a radiological confirmation of fistula closure. Cox regression analysis was performed to evaluate factors predictive of achieving remission without need for surgery. Of 6081 CD patients screened, 97 had entero-urinary fistulas (frequency 1.6%). Seventy-five percent of fistulas occurred in men. After a median follow-up of 91 months, 96% of patients were in sustained remission. Thirty-three patients (35%) received anti-tumour necrosis factor (TNF) therapy. Of these, 45% achieved sustained remission (median follow-up 35 months) without needing surgery. More than 80% of patients required surgery, which induced remission (median follow-up 101 months) in 99% of them. Only the use of anti-TNF agents was associated with an increased rate of remission without need for surgery (hazard ratio 0.23, 95% confidence interval 0.12-0.44; p In this large cohort of CD patients, the frequency of entero-urinary fistulas was lower than previously described. More than 80% of patients required surgery, and in all but one of them surgery induced sustained remission. In a selected subgroup of patients, anti-TNF may induce long-term fistula remission and radiographic closure, making it possible to avoid surgery.
Description
MeSH Terms
Adalimumab
Adolescent
Adult
Aged
Aged, 80 and over
Anti-bacterial agents
Anti-inflammatory agents
Case-control studies
Combined modality therapy
Crohn disease
Female
Follow-up studies
Humans
Infliximab
Intestinal fistula
Male
Mercaptopurine
Middle aged
Proportional hazards models
Remission induction
Retrospective studies
Treatment outcome
Ureteral diseases
Urinary bladder diseases
Urinary fistula
Young adult
Adolescent
Adult
Aged
Aged, 80 and over
Anti-bacterial agents
Anti-inflammatory agents
Case-control studies
Combined modality therapy
Crohn disease
Female
Follow-up studies
Humans
Infliximab
Intestinal fistula
Male
Mercaptopurine
Middle aged
Proportional hazards models
Remission induction
Retrospective studies
Treatment outcome
Ureteral diseases
Urinary bladder diseases
Urinary fistula
Young adult
DeCS Terms
Antibacterianos
Antiinflamatorios
Enfermedad de Crohn
Enfermedades ureterales
Enfermedades de la vejiga urinaria
Fístula intestinal
Fístula urinaria
Terapia combinada
Antiinflamatorios
Enfermedad de Crohn
Enfermedades ureterales
Enfermedades de la vejiga urinaria
Fístula intestinal
Fístula urinaria
Terapia combinada
CIE Terms
Keywords
Crohn’s disease, Adalimumab, Anti-TNF, Entero-urinary fistula, Enterovesical fistula, Infliximab
Citation
Taxonera C, Barreiro-de-Acosta M, Bastida G, Martinez-Gonzalez J, Merino O, García-Sánchez V, et al. Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease. J Crohns Colitis. 2016 Jun;10(6):657-62